Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UP-002
- Development stage
- Preclinical
- Lead developer
- U-Ploid Biotechnologies
01
Overview
UP-002 is an early-stage therapeutic candidate currently in the discovery phase, developed by U-Ploid Biotechnologies. As of early 2026, specific details concerning its molecular target, modality, and therapeutic indication remain undisclosed by the developer. However, the candidate is part of a specialized research pipeline focused on meiotic aneuploidy and the correction of chromosome segregation errors in oocytes. This broader program aims to improve success rates in assisted reproductive technologies, such as in vitro fertilization (IVF), by reducing the incidence of chromosomal abnormalities during egg development.
Beyond the preview
Go deeper on UP-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UP-002.